title: Tumefactive multiple sclerosis lesions under fingolimod treatment.
authors.affiliation: Department of Neurology, Sint Lucas Andreas Hospital, Amsterdam, the Netherlands. f.visser@slaz.nl
authors.forename: Femke
authors.initials: F
authors.lastname: Visser
authors.forename: Mike P
authors.initials: MP
authors.lastname: Wattjes
authors.forename: Petra J W
authors.initials: PJ
authors.lastname: Pouwels
authors.forename: Wim H J P
authors.initials: WH
authors.lastname: Linssen
authors.forename: Bob W
authors.initials: BW
authors.lastname: van Oosten
mesh_terms: D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D001921:Brain / Q000473:pathology*; D002794:Choline / Q000378:metabolism; D005260:Female; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007294:Inositol / Q000378:metabolism; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology*; D009413:Nerve Fibers, Myelinated / Q000473:pathology*; D011409:Propylene Glycols / Q000627:therapeutic use*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D001224:Aspartic Acid; D007294:Inositol; C000179:N-acetylaspartate; D000068876:Fingolimod Hydrochloride; D002794:Choline; D013110:Sphingosine